Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
BUSINESS
Takeda in Talks with Shire after 3 Buyout Proposals Rejected
Takeda Pharmaceutical has made three proposals to London-listed Shire regarding its potential offer for the Dublin maker, which were all rejected, the two companies revealed on April 19, confirming earlier reports by Reuters. Their talks are still ongoing, they said.…
To read the full story
Related Article
- Grilled by Shareholders, Takeda CEO Seeks Understanding for Shire Deal
June 29, 2018
- Takeda Shareholders Strike Down Dissident Group’s Proposal
June 28, 2018
- Angry Shareholders Say Don’t Make Takeda a Debt-Saddled Company
June 12, 2018
- Takeda’s Founding Family-Backed Shareholders Demand Prior Vote for 1 Trillion Yen-Plus Deals
June 6, 2018
- Takeda Confident It Can Reduce Debt Quickly after Shire Takeover: CEO
May 11, 2018
- Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
May 9, 2018
- Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
- Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
- Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
- Takeda Mulls Takeover Bid for Shire
March 29, 2018
BUSINESS
- Fuso Grabs Japan Rights to Dimerix’s Kidney Disease Drug
January 8, 2025
- Mitsubishi Tanabe Gets Taiwan Rights for Rigel/Kissei’s ITP Drug
January 8, 2025
- Daiichi Sankyo to Transfer Avastin Biosimilar to Amgen in Japan
January 8, 2025
- BMS Taps Ex-Lilly Exec Katsuma as Japan Chief, Sugino as Asia-Pacific GM
January 7, 2025
- Biogen Japan Chief Hopes to Build Momentum in ALS Space Riding on Success with Qalsody
January 7, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…